References

1. Structure-based drug design [Review article] L Mario Amzel, Current Opinion in Biotechnology 1998, 9:366-369.
2. Conformation Space Mapping - A Novel Method for Structure Based Drug Design. Oren Becker Folding & Design 1996, 1:A16.
3. Can drugs be designed? [Review article], Roderick E Hubbard, Current Opinion in Biotechnology 1997, 8:696-700.
4. Structure-based drug design and informatics: the development of potent HIV protease inhibitors as clinical drug candidates. Keith D. Watenpaugh, Folding & Design 1996, 1:A169.
5. Software for structure-based drug design [Review article] Wayne C Guida, Current Opinion in Structural Biology 1994, 4:777-781.
6. Structure-based drug design: progress, results and challenges [Review article], Christophe LMJ Verlinde, Wim GJ Hol, Structure 1994, 2:577-587.
7. Serendipity meets precision: the integration of structure-based drug design and combinatorial chemistry for efficient drug discovery. [Minireview] F Raymond Salemme, John Spurlino, Roger Bone, Structure 1997, 5:319-324.
8. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor -APA R 95845 at 2.8 Å resolution. J Ding, K Das, C Tantillo, W Zhang, AD Clark, Jr, S Jessen, X Lu, Y Hsiou, A Jacobo-Molina, K Andries,R Pauwels, H Moereels, L Koymans, PAJ Janssen, RH Smith, Jr, M Kroeger Koepke, CJ Michejda, SH Hughes, E Arnold, Structure 1995, 3:365-379.
9. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. Daniel K Gehlhaar, Gennady M Verkhivker, Paul A Rejto, Christopher J Sherman, David B Fogel, Lawrence J Fogel, Stephan T Freer, Chemistry & Biology 1995, 2:317-324.
10. The complex of the anti-cancer therapeutic, BW1843U89, with thymidylate synthase at 2.0 Å resolution: implications for a new mode of inhibition. Thomas J Stout, Robert M Stroud, Structure 1996, 4:67-77.
11. Protein-drug complexes important for immunoregulation and organ transplantation. [Review article] Manuel A Navia, Current Opinion in Structural Biology 1996, 6:838-847.
12. Sialidases: structures, biological significance and therapeutic potential. [Review article] Garry Taylor, Current Opinion in Structural Biology 1996, 6:830-837.
13. Drug-DNA interactions. [Review article], Jonathan B Chaires, Current Opinion in Structural Biology 1998, 8:314-320.
14. 'Flu' and structure-based drug design [Minireview], Rebecca C Wade, Structure 1997, 5:1139-1145.
15. Update on computer-aided drug design [Review article], Robert C Jackson, Current Opinion in Biotechnology 1995, 6:646-651.
16. The new partnership of genomics and chemistry for accelerated drug development. [Review article], Daniel F Veber, Fred H Drake, Maxine Gowen, Current Opinion in Chemical Biology 1997, 1:151-156.
17. Structural analysis of nucleic acid aptamers. [Review article], Dinshaw J Patel, Current Opinion in Chemical Biology 1997, 1:32-46.
18. Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design. Robert A. Grant, Chaitanya N. Hiremath, David J. Filman, Rashid Syed, Koen Andries, James M. Hogle, Current Biology 1994, 4:784-797.
19. Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin. D. Ellen K Kick, Diana C Roe, A Geoffrey Skillman, Guangcheng Liu, Todd JA Ewing, Yaxiong Sun, Irwin D Kuntz, Jonathan A Ellman, Chemistry & Biology 1997, 4:297-307.
20. Modelling and Design. Edward Croft, Sarah Done, Pavel Herzyk, Roderick Hubbard, Folding & Design 1996, 1:A38.
21. Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes. Ulrike Obst, David W Banner, Lutz Weber, Francois Diederich, Chemistry & Biology 1997, 4:287-295.
22. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. Eric T Baldwin, T Narayana Bhat, Sergei Gulnik, Beishan Liu, Igor A Topol, Yoshiaki Kiso, Tsutomu Mimoto, Hiroaki Mitsuya, John W Erickson, Structure 1995, 3:581-590.
23. Design of proteins with selected thermal properties. Michael P Morrissey, Eugene I Shakhnovich, Folding & Design 20 Sep 1996, 1:391-405.
24. Surprising leads for a cholera toxin receptor-binding antagonist: crystallographic studies of CTB mutants. Ethan A Merritt, Steve Sarfaty, The-tsai Chang, Leslie M Palmer, Michael G Jobling, Randall K Holmes,Wim GJ Hol, Structure 1995, 3:561-570.